Journal article
Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab
MC Gillies, A Campain, R Walton, JM Simpson, JJ Arnold, RH Guymer, IL McAllister, AP Hunyor, RW Essex, N Morlet, D Barthelmes
Ophthalmology | Published : 2015
Abstract
Purpose To characterize in more detail routine treatment patterns of intravitreal ranibizumab for neovascular age-related macular degeneration (nAMD), we analyzed the length of time and the number of injections required until lesions with choroidal neovascularization (CNV) were first graded inactive. Design Database observational study. Participants Treatment-naïve eyes receiving predominantly ranibizumab for nAMD in routine clinical practice that were tracked in the Fight Retinal Blindness! observational registry. Methods Eyes treated with ranibizumab were followed until CNV was first reported to be "inactive" (i.e., absence of intraretinal fluid and hemorrhages). Main Outcome Measures The ..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
M.C.G.: Sydney Medical Foundation Fellow; Support - NHMRC practitioner fellowship; Advisory board - Novartis, Bayer, and Allergan. J.J.A.: Personal fees and nonfinancial support - Novartis Pharmaceuticals and Bayer Pharmaceuticals, outside the submitted work. A.P.H.: Support - Novartis and Bayer. D.B.: Support - Walter and Gertrud Siegenthaler Foundation, Zurich, Switzerland, and the Swiss National Foundation. Supported by a grant from the Royal Australian and New Zealand College of Ophthalmologists Eye Foundation (2007-2009) and a grant from the National Health and Medical Research Council (grant no. 632663), Australia (NHRMC 2010-2012). Funding was also provided by Novartis and Bayer. These supporting organizations had no role in the design or conduct of the research.